CYP2C9 and CYP2C19 polymorphic forms are related to increased indisularn exposure and higher risk of severe hematologic toxicity

A.S. Zandvliet, A.D.R. Huitema, W Copalu, Y. Yamada, T. Tamura, J.H. Beijnen, J.H.M. Schellens

Research output: Contribution to journal › Article › Academic › peer-review

Cite this

@article{aa6dbdfe944a4e0593074df5e71e668b,

title = "CYP2C9 and CYP2C19 polymorphic forms are related to increased indisularn exposure and higher risk of severe hematologic toxicity",

author = "A.S. Zandvliet and A.D.R. Huitema and W Copalu and Y. Yamada and T. Tamura and J.H. Beijnen and J.H.M. Schellens",

note = "1078-0432 FIGON Medicines Days 2007",

year = "2007",

language = "Undefined/Unknown",

volume = "13",

pages = "2970--2976",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - CYP2C9 and CYP2C19 polymorphic forms are related to increased indisularn exposure and higher risk of severe hematologic toxicity

AU - Zandvliet, A.S.

AU - Huitema, A.D.R.

AU - Copalu, W

AU - Yamada, Y.

AU - Tamura, T.

AU - Beijnen, J.H.

AU - Schellens, J.H.M.

N1 - 1078-0432 FIGON Medicines Days 2007

PY - 2007

Y1 - 2007

M3 - Article

SN - 1078-0432

VL - 13

SP - 2970

EP - 2976

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 10

ER -